Phaseline

Companies › Immunomic Therapeutics

Immunomic Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Immunology, Oncology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ITI-5000
Self-amplifying RNA vaccine targeting HERV-K and CT83 fused with LAMP-1
HERVK, CT83, LAMP1Phase 1Triple Negative Breast Cancer (TNBC)Feb 2028
ITI-9001
self-amplifying RNA (saRNA) immunotherapy encoding CryJ2-LAMP-1 fusion protein
–Phase 1Allergen ImmunotherapyFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07726147ITI-9001Phase 1Allergen ImmunotherapyImmunologyFeb 2028
NCT07652242ITI-5000Phase 1Triple Negative Breast Cancer (TNBC)OncologyFeb 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

HERVK (1) CT83 (1) LAMP1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.